Beruflich Dokumente
Kultur Dokumente
22
december 5, 2015
vol l no 49
EPW
COMMENTARY
vol l no 49
EPW
december 5, 2015
To Control or Not
Regulation of pharmaceutical prices is
not specific to India alone and in several
Organisation for Economic Co-operation
and Development (OECD) countries where
various forms of pricing policies exist,
the pharmaceutical companies are willing to negotiate a lower price to gain
entry to these markets.3 This suggests
that there may not be an immediate
threat to availability from instituting
lower prices, given that there is scope for
earnings to be made from the sheer size
of the market.
But in the present scenario, accessibility does seem like a potential concern.
According to the Economic Survey of
India 201415, Indias per capita net national income is Rs 88,533 while the
highest cost of treatment amongst the 12
drugs recommended by the NPPA is
4
5
23
COMMENTARY
References
Bloom, D E, Elizabeth T Cafiero-Fonseca, Vanessa
Candeias, Eli Adashi, Lakshmi Reddy Bloom,
Lauren Gurfein, Eva Jan-Llopis, Alyssa Lubet,
Elizabeth Mitgang, Jennifer Carroll OBrien
and Akshar Saxena (2014): Economics of NonCommunicable Diseases in India: The Costs
and Returns on Investment of Interventions to
Promote Healthy Living and Prevent, Treat,
and Manage NCDs, World Economic Forum,
Harvard School of Public Health.
Hillner, Bruce E and Thomas J Smith (2009): Efficacy Does Not Necessarily Translate to Cost
24
december 5, 2015
vol l no 49
EPW